Last reviewed · How we verify
Placebo of MCI-186
Placebo of MCI-186 is a Small molecule drug developed by Tanabe Pharma Corporation. It is currently in Phase 3 development for Control arm in phase 3 trials for amyotrophic lateral sclerosis (ALS).
This is a placebo control arm and contains no active pharmaceutical ingredient.
This is a placebo control arm and contains no active pharmaceutical ingredient. Used for Control arm in phase 3 trials for amyotrophic lateral sclerosis (ALS).
At a glance
| Generic name | Placebo of MCI-186 |
|---|---|
| Sponsor | Tanabe Pharma Corporation |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
As a placebo, this formulation is pharmacologically inert and serves as a control comparator in clinical trials. It is used to establish the efficacy and safety profile of the active drug MCI-186 (edaravone) by comparison against a non-therapeutic baseline. The placebo arm allows for assessment of disease progression and spontaneous adverse events independent of active drug effects.
Approved indications
- Control arm in phase 3 trials for amyotrophic lateral sclerosis (ALS)
Common side effects
Key clinical trials
- A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects (PHASE1)
- Research of Traditional Chinese Medicine Oral Preparation of C. Cicadae in the Treatment of ALS Patients With Elevated Plasma Sphingolipids (PHASE2)
- Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke (PHASE2)
- Dose Finding Study of MCI-186 in Acute Ischemic Stroke (PHASE2)
- Study of Oral Edaravone in Healthy Adult Males (PHASE1)
- Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (PHASE3)
- Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS) (PHASE3)
- Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of MCI-186 CI brief — competitive landscape report
- Placebo of MCI-186 updates RSS · CI watch RSS
- Tanabe Pharma Corporation portfolio CI
Frequently asked questions about Placebo of MCI-186
What is Placebo of MCI-186?
How does Placebo of MCI-186 work?
What is Placebo of MCI-186 used for?
Who makes Placebo of MCI-186?
What development phase is Placebo of MCI-186 in?
Related
- Manufacturer: Tanabe Pharma Corporation — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Control arm in phase 3 trials for amyotrophic lateral sclerosis (ALS)
- Compare: Placebo of MCI-186 vs similar drugs
- Pricing: Placebo of MCI-186 cost, discount & access